# A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

> **NCT06973291** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 606 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Zasocitinib
- **DRUG:** Deucravacitinib
- **DRUG:** Placebo to match zasocitinib
- **DRUG:** Placebo to match deucravacitinib

## Key facts

- **NCT ID:** NCT06973291
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-09
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-04-22
- **Target enrollment:** 606 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973291, "A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06973291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*